Skip to main content
Samuel Yamshon, MD, Oncology, New York, NY

SamuelYamshonMD

Oncology • New York, NY

Hematologic Oncology

Fellow

Request Appointment

Overview of Dr. Yamshon

Dr. Samuel Yamshon is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and New York-Presbyterian Hospital. He received his medical degree from University of California, Davis, School of Medicine and has been in practice 0 years. He is one of 376 doctors at New York-Presbyterian Hospital and one of 376 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 20 publications and over 100 citings.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2016 - 2019
  • University of California, Davis, School of Medicine
    University of California, Davis, School of MedicineClass of 2016

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2019 - 2027
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Markers of Lenalidomide and Rituximab Treatment in Indolent Non-Hodgkins Lymphoma
    Yamshon S, Qi L, et al., UC Davis Research Symposium, UC Davis, 4/2014
  • Correlative Analysis and Clinical Update Of a Phase II Study Using Lenalidomide and Rituximab In Patients With Indolent Non-Hodgkin Lymphoma.
    Yamshon S, Qi L, Yu C, et al., Blood, 12/2013

Lectures

  • Non-Destructive Post-Transplant Lymphoproliferative Disorder Shows Distinct Clinical Features with HHV-6 Reactivation in a Subset 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Bioethics and Transgender Health 
    University of Pennsylvania - 10/2014
  • Ethical Decision-Making 
    Harvard University - 10/2014
  • Join now to see all

Press Mentions

  • The Battle for Frontline Therapy on MCL: Lenalidomide plus Rituximab
    The Battle for Frontline Therapy on MCL: Lenalidomide plus RituximabMarch 2nd, 2021
  • Mantle Cell Lymphoma: Long-Extending Remissions with Lenalidomide, Rituximab
    Mantle Cell Lymphoma: Long-Extending Remissions with Lenalidomide, RituximabDecember 16th, 2020

Professional Memberships

Dr. Samuel Yamshon, Dr. Samuel Yamshon, MD, Dr. S Yamshon